Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.19
NYSE:LCI's Cash-to-Debt is ranked lower than
87% of the 886 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.53 vs. NYSE:LCI: 0.19 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:LCI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 1.07 Max: 228.13
Current: 0.19
0
228.13
Equity-to-Asset 0.36
NYSE:LCI's Equity-to-Asset is ranked lower than
83% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. NYSE:LCI: 0.36 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:LCI' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.17  Med: 0.7 Max: 0.92
Current: 0.36
-0.17
0.92
Debt-to-Equity 1.50
NYSE:LCI's Debt-to-Equity is ranked lower than
90% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. NYSE:LCI: 1.50 )
Ranked among companies with meaningful Debt-to-Equity only.
NYSE:LCI' s Debt-to-Equity Range Over the Past 10 Years
Min: -6.43  Med: 0.11 Max: 38.67
Current: 1.5
-6.43
38.67
Debt-to-EBITDA 3.97
NYSE:LCI's Debt-to-EBITDA is ranked lower than
74% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. NYSE:LCI: 3.97 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NYSE:LCI' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -289.65  Med: 0.47 Max: 6.57
Current: 3.97
-289.65
6.57
Interest Coverage 1.97
NYSE:LCI's Interest Coverage is ranked lower than
92% of the 683 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 132.39 vs. NYSE:LCI: 1.97 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:LCI' s Interest Coverage Range Over the Past 10 Years
Min: 1.97  Med: 39.74 Max: 1115.01
Current: 1.97
1.97
1115.01
Piotroski F-Score: 5
Altman Z-Score: 1.57
Beneish M-Score: -2.63
WACC vs ROIC
4.62%
7.42%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 26.07
NYSE:LCI's Operating Margin % is ranked higher than
88% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.96 vs. NYSE:LCI: 26.07 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:LCI' s Operating Margin % Range Over the Past 10 Years
Min: -7.49  Med: 11.29 Max: 56.73
Current: 26.07
-7.49
56.73
Net Margin % 7.49
NYSE:LCI's Net Margin % is ranked higher than
55% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.73 vs. NYSE:LCI: 7.49 )
Ranked among companies with meaningful Net Margin % only.
NYSE:LCI' s Net Margin % Range Over the Past 10 Years
Min: -3.2  Med: 5.87 Max: 36.85
Current: 7.49
-3.2
36.85
ROE % 8.50
NYSE:LCI's ROE % is ranked higher than
56% of the 857 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.75 vs. NYSE:LCI: 8.50 )
Ranked among companies with meaningful ROE % only.
NYSE:LCI' s ROE % Range Over the Past 10 Years
Min: -3.32  Med: 8.85 Max: 39.56
Current: 8.5
-3.32
39.56
ROA % 2.90
NYSE:LCI's ROA % is ranked lower than
52% of the 888 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.29 vs. NYSE:LCI: 2.90 )
Ranked among companies with meaningful ROA % only.
NYSE:LCI' s ROA % Range Over the Past 10 Years
Min: -2.12  Med: 4.71 Max: 35.21
Current: 2.9
-2.12
35.21
ROC (Joel Greenblatt) % 34.33
NYSE:LCI's ROC (Joel Greenblatt) % is ranked higher than
78% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.64 vs. NYSE:LCI: 34.33 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:LCI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -11.64  Med: 26.35 Max: 133.12
Current: 34.33
-11.64
133.12
3-Year Revenue Growth Rate 30.30
NYSE:LCI's 3-Year Revenue Growth Rate is ranked higher than
92% of the 681 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. NYSE:LCI: 30.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:LCI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -20.8  Med: 14 Max: 91.7
Current: 30.3
-20.8
91.7
3-Year EBITDA Growth Rate 13.00
NYSE:LCI's 3-Year EBITDA Growth Rate is ranked higher than
56% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.90 vs. NYSE:LCI: 13.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:LCI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 13 Max: 153.4
Current: 13
0
153.4
GuruFocus has detected 3 Warning Signs with Lannett Co Inc NYSE:LCI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:LCI's 30-Y Financials

Financials (Next Earnings Date: 2018-05-02)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2017

LCI Guru Trades in Q1 2017

Paul Tudor Jones 14,800 sh (+49.49%)
Richard Snow 3,093,435 sh (+22.48%)
Joel Greenblatt 695,498 sh (+12.43%)
Ronald Muhlenkamp 486,510 sh (-3.54%)
» More
Q2 2017

LCI Guru Trades in Q2 2017

Paul Tudor Jones 25,188 sh (+70.19%)
Richard Snow 3,152,240 sh (+1.90%)
Joel Greenblatt Sold Out
Ronald Muhlenkamp 486,060 sh (-0.09%)
» More
Q3 2017

LCI Guru Trades in Q3 2017

Chuck Royce 590 sh (New)
Richard Snow 3,435,152 sh (+8.97%)
Paul Tudor Jones Sold Out
Ronald Muhlenkamp 454,873 sh (-6.42%)
» More
Q4 2017

LCI Guru Trades in Q4 2017

Paul Tudor Jones 9,331 sh (New)
Steven Cohen 84,037 sh (New)
Ronald Muhlenkamp 433,134 sh (-4.78%)
Richard Snow 3,037,816 sh (-11.57%)
Chuck Royce 396 sh (-32.88%)
» More
» Details

Insider Trades

Latest Guru Trades with LCI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ronald Muhlenkamp 2017-12-31 Reduce -4.78%0.13%$19.9 - $29.25 $ 15.85-35%433,134
Ronald Muhlenkamp 2017-09-30 Reduce -6.42%0.2%$15.1 - $22.7 $ 15.85-14%454,873
Ronald Muhlenkamp 2017-06-30 Reduce -0.09%$18.45 - $27.15 $ 15.85-27%486,060
Joel Greenblatt 2017-06-30 Sold Out 0.2%$18.45 - $27.15 $ 15.85-27%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:SZSE:002923, BOM:530549, XKRX:092040, XKRX:065660, XKRX:243070, ROCO:4123, SZSE:300436, XKRX:183490, SHSE:600530, SZSE:002864, NAS:ADMS, NAS:RIGL, SZSE:002728, SHSE:603998, CAI:PHAR, TSE:3151, TSX:TRST, XKRX:271980, SZSE:300584, SZSE:000790 » details
Traded in other countries:LN5.Germany,
Headquarter Location:USA
Lannett Co Inc develops, manufactures, packages, markets and distributes generic versions of branded pharmaceutical products. Its products include solid oral dosage forms, including oral solutions, nasal, topicals or parentarels.

Lannett Co Inc develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. It offers solid oral, extended release, topical, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, soft gel, and injectable dosages. It also provides its products for various medical indications comprising glaucoma, Gastrointestinal, Migraine, Obesity, and Respiratory.

Ratios

vs
industry
vs
history
PE Ratio 12.48
LCI's PE Ratio is ranked higher than
86% of the 584 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.44 vs. LCI: 12.48 )
Ranked among companies with meaningful PE Ratio only.
LCI' s PE Ratio Range Over the Past 10 Years
Min: 7.92  Med: 22.77 Max: 222.5
Current: 12.48
7.92
222.5
Forward PE Ratio 5.76
LCI's Forward PE Ratio is ranked higher than
94% of the 111 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.00 vs. LCI: 5.76 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 12.48
LCI's PE Ratio without NRI is ranked higher than
86% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.44 vs. LCI: 12.48 )
Ranked among companies with meaningful PE Ratio without NRI only.
LCI' s PE Ratio without NRI Range Over the Past 10 Years
Min: 7.92  Med: 22.77 Max: 222.5
Current: 12.48
7.92
222.5
Price-to-Owner-Earnings 4.89
LCI's Price-to-Owner-Earnings is ranked higher than
95% of the 320 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.72 vs. LCI: 4.89 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
LCI' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.44  Med: 18.04 Max: 834.91
Current: 4.89
4.44
834.91
PB Ratio 0.98
LCI's PB Ratio is ranked higher than
89% of the 843 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.96 vs. LCI: 0.98 )
Ranked among companies with meaningful PB Ratio only.
LCI' s PB Ratio Range Over the Past 10 Years
Min: 0.61  Med: 1.55 Max: 6.39
Current: 0.98
0.61
6.39
PS Ratio 0.94
LCI's PS Ratio is ranked higher than
85% of the 784 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.25 vs. LCI: 0.94 )
Ranked among companies with meaningful PS Ratio only.
LCI' s PS Ratio Range Over the Past 10 Years
Min: 0.48  Med: 1.34 Max: 7.1
Current: 0.94
0.48
7.1
Price-to-Free-Cash-Flow 5.06
LCI's Price-to-Free-Cash-Flow is ranked higher than
92% of the 216 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.03 vs. LCI: 5.06 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
LCI' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 3.22  Med: 17.78 Max: 213.77
Current: 5.06
3.22
213.77
Price-to-Operating-Cash-Flow 3.44
LCI's Price-to-Operating-Cash-Flow is ranked higher than
94% of the 289 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.21 vs. LCI: 3.44 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
LCI' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 2.89  Med: 14.04 Max: 288.5
Current: 3.44
2.89
288.5
EV-to-EBIT 7.81
LCI's EV-to-EBIT is ranked higher than
91% of the 599 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.78 vs. LCI: 7.81 )
Ranked among companies with meaningful EV-to-EBIT only.
LCI' s EV-to-EBIT Range Over the Past 10 Years
Min: -277  Med: 11.5 Max: 398
Current: 7.81
-277
398
EV-to-EBITDA 5.91
LCI's EV-to-EBITDA is ranked higher than
92% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.59 vs. LCI: 5.91 )
Ranked among companies with meaningful EV-to-EBITDA only.
LCI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -748.5  Med: 10.1 Max: 3667
Current: 5.91
-748.5
3667
EV-to-Revenue 2.06
LCI's EV-to-Revenue is ranked higher than
66% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. LCI: 2.06 )
Ranked among companies with meaningful EV-to-Revenue only.
LCI' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.4  Med: 1.6 Max: 7.6
Current: 2.06
0.4
7.6
PEG Ratio 0.22
LCI's PEG Ratio is ranked higher than
97% of the 318 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.00 vs. LCI: 0.22 )
Ranked among companies with meaningful PEG Ratio only.
LCI' s PEG Ratio Range Over the Past 10 Years
Min: 0.07  Med: 0.37 Max: 16.62
Current: 0.22
0.07
16.62
Shiller PE Ratio 17.69
LCI's Shiller PE Ratio is ranked higher than
82% of the 230 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.11 vs. LCI: 17.69 )
Ranked among companies with meaningful Shiller PE Ratio only.
LCI' s Shiller PE Ratio Range Over the Past 10 Years
Min: 17.28  Med: 72.5 Max: 1389
Current: 17.69
17.28
1389
Current Ratio 2.32
LCI's Current Ratio is ranked lower than
54% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.56 vs. LCI: 2.32 )
Ranked among companies with meaningful Current Ratio only.
LCI' s Current Ratio Range Over the Past 10 Years
Min: 0.96  Med: 2.39 Max: 10.52
Current: 2.32
0.96
10.52
Quick Ratio 1.77
LCI's Quick Ratio is ranked lower than
55% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.02 vs. LCI: 1.77 )
Ranked among companies with meaningful Quick Ratio only.
LCI' s Quick Ratio Range Over the Past 10 Years
Min: 0.26  Med: 1.69 Max: 9.3
Current: 1.77
0.26
9.3
Days Inventory 131.61
LCI's Days Inventory is ranked lower than
58% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 116.78 vs. LCI: 131.61 )
Ranked among companies with meaningful Days Inventory only.
LCI' s Days Inventory Range Over the Past 10 Years
Min: 68.82  Med: 115.5 Max: 165.34
Current: 131.61
68.82
165.34
Days Sales Outstanding 146.39
LCI's Days Sales Outstanding is ranked lower than
84% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.10 vs. LCI: 146.39 )
Ranked among companies with meaningful Days Sales Outstanding only.
LCI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 78.9  Med: 108.89 Max: 171.98
Current: 146.39
78.9
171.98
Days Payable 81.15
LCI's Days Payable is ranked higher than
55% of the 640 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.92 vs. LCI: 81.15 )
Ranked among companies with meaningful Days Payable only.
LCI' s Days Payable Range Over the Past 10 Years
Min: 49.15  Med: 74.51 Max: 88.36
Current: 81.15
49.15
88.36

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.20
LCI's 3-Year Average Share Buyback Ratio is ranked higher than
69% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. LCI: -1.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
LCI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -37  Med: -5.5 Max: 26.7
Current: -1.2
-37
26.7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.40
LCI's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
96% of the 312 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.58 vs. LCI: 0.40 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
LCI' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.4  Med: 1.34 Max: 5.86
Current: 0.4
0.4
5.86
Price-to-Median-PS-Value 0.70
LCI's Price-to-Median-PS-Value is ranked higher than
79% of the 692 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.08 vs. LCI: 0.70 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
LCI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.51  Med: 1.23 Max: 8.34
Current: 0.7
0.51
8.34
Price-to-Peter-Lynch-Fair-Value 0.50
LCI's Price-to-Peter-Lynch-Fair-Value is ranked higher than
93% of the 188 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.50 vs. LCI: 0.50 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
LCI' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.36  Med: 1.13 Max: 15.96
Current: 0.5
0.36
15.96
Earnings Yield (Greenblatt) % 12.79
LCI's Earnings Yield (Greenblatt) % is ranked higher than
94% of the 888 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.96 vs. LCI: 12.79 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
LCI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -13.2  Med: 6 Max: 20
Current: 12.79
-13.2
20
Forward Rate of Return (Yacktman) % 32.63
LCI's Forward Rate of Return (Yacktman) % is ranked higher than
98% of the 414 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.53 vs. LCI: 32.63 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
LCI' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 0.7  Med: 5.9 Max: 33.5
Current: 32.63
0.7
33.5

More Statistics

Revenue (TTM) (Mil) $640.10
EPS (TTM) $ 1.27
Beta1.82
Volatility56.00%
52-Week Range $14.40 - 30.35
Shares Outstanding (Mil)37.84

Analyst Estimate

Jun18 Jun19 Jun20
Revenue (Mil $) 713 680 672
EBIT (Mil $)
EBITDA (Mil $) 263 249 239
EPS ($) 3.20 2.92 2.75
EPS without NRI ($) 3.20 2.92 2.75
EPS Growth Rate
(Future 3Y To 5Y Estimate)
-2.00%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}